Clinical Trial Detail

NCT ID NCT02008227
Title A Randomized Phase 3 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) Compared to Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - OAK
Recruitment Completed
Gender both
Phase Phase III
Variant Requirements No
Sponsors Hoffmann-La Roche
Indications

lung non-small cell carcinoma

Therapies

Docetaxel

Atezolizumab

Age Groups: adult

No variant requirements are available.